Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Trophos Appoints JSB Partners as Global Partnership Advisor

Published: Monday, December 31, 2012
Last Updated: Monday, December 31, 2012
Bookmark and Share
Life science advisor to advise Trophos on strategic partnerships for orphan disease and niche indication candidates.

Trophos SA has announced the appointment of JSB Partners, a global life sciences advisor.

JSB Partners has been selected by Trophos to assist the company in executing its business development objectives. These aim to put in place strategic partnerships for Trophos’ advanced clinical development programs:

• Olesoxime, which is presently being tested in a pivotal trial in Spinal Muscular Atrophy (SMA) with results due in the second half of 2013;
• Olesoxime for Multiple Sclerosis (MS) disease progression, with a phase II proof-of-concept trial designed with global MS experts, ready to be initiated leading to results in 2016;
• TRO40303, in an ongoing phase IIa proof-of-concept study in cardiac ischemia-reperfusion injury (IRI), with results due in the first half of 2013

“Trophos has always followed a unique path, forming consortia to work on high medical need orphan or niche indications with no existing treatments,” said Christine Placet, CEO Trophos.

Placet continued, “The expertise of world leading specialists within these conditions has contributed to and enhanced the Trophos pipeline. Both the market potential of our candidates - nearly USD two billion, as well as the patients suffering from terrible orphan diseases and conditions, deserve optimal partnerships to advance therapies and cures for these conditions. This is why we have appointed some of the best advisors to help us.”

“There is considerable market potential for the conditions targeted by the Trophos pipeline,” said Michel Gouy, partner, JSB-Partners. “It is critical to find the right partnerships for continued advancement in treatment for these conditions.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Trophos Announces Top-Line Results in Pivotal Trial of Olesoxime in SMA
Promising results for the maintenance of motor function in spinal muscular atrophy - a rare, serious and debilitating pediatric-onset neurodegenerative disease.
Thursday, March 20, 2014
Trophos Completes Pivotal Phase II/III Study of Olesoxime in SMA
The French patients’ association AFM-Telethon supported the study which evaluates the ability of olesoxime to preserve the neuromuscular function of SMA patients.
Friday, November 08, 2013
Trophos Announces Final Patient Completion of Phase II Study of TRO40303
The study, a critical part of the EU funded MitoCare Project, will evaluate the reduction of reperfusion injury by TRO40303 in acute ST-elevation myocardial infarction (STEMI) patients.
Thursday, October 03, 2013
Trophos Launches First Study of Olesoxime in Multiple Sclerosis Patients
A Phase 1b study in RRMS patients is starting in three MS reference centers in France.
Tuesday, March 19, 2013
Trophos Announces Positive Interim Review in Pivotal Study of Olesoxime in SMA
Topline results expected in the fourth quarter of 2013.
Monday, March 04, 2013
Trophos Program Boosted by EUR 1 Million Grant for Olesoxime in Progressive MS
Agence Nationale de la Recherche awards second grant to Trophos led consortium for Phase Ib/IIa clinical study.
Friday, October 12, 2012
Marceline Clementine Appointed Chief Financial Officer
Ms. Clementine is now responsible for all administrative and financial services at Trophos.
Wednesday, September 19, 2012
Trophos Announces Conclusion of MitoTarget Consortium
EU funded 3-year project spearheaded by orphan disease specialist Trophos reports results from neurodegenerative program to the European Commission.
Wednesday, August 01, 2012
Trophos Appoints Christine Placet as Chief Executive Officer
Christine becomes CEO under a succession plan designed to provide continuity for Trophos.
Thursday, June 14, 2012
Trophos Announces Results of Phase III Study of Olesoxime in ALS
Company continues its ongoing programs and financed until at least the end of 2013.
Wednesday, December 14, 2011
Trophos Initiates Phase II Study for Novel Cardioprotective Compound, TRO40303, in Acute MI
European study being performed as part of Trophos-led, EU funded MitoCare project.
Tuesday, November 01, 2011
Trophos Completes Patient Enrolment in Pivotal Efficacy Study of Olesoxime in SMA
Topline results expected in second half of 2013.
Friday, September 09, 2011
Trophos Successfully Completes Phase 1 Study for Novel Cardioprotective Compound, TRO40303
Phase 2 proof-of-concept study in acute myocardial infarction planned for second half 2011 with MitoCare EU consortium.
Friday, February 25, 2011
Trophos to Lead new MitoCare Consortium Awarded EUR 6 Million to Study Cardioprotective Compound, TRO40303
Program of translational research to study innovative approaches to reducing cardiac ischemia-reperfusion injury.
Wednesday, December 15, 2010
Trophos Initiates Pivotal Efficacy Study of Olesoxime in Spinal Muscular Atrophy
European study supported by partnership with the Association Française contre les Myopathies.
Monday, October 18, 2010
Scientific News
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Researchers Find Key Player in Diabetic Kidney Disease Through Power of Metabolomics
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!